HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer, His & Avi, Human
| ¥9900 | |
| Z06646-100 | |
| 
                                             | 
            |
| 
                        
                             | 
                |
| 
                         | 
                |
| ¥9900 | |
| Z06646-100 | |
| 
                                             | 
            |
| 
                        
                             | 
                |
| 
                         | 
                |
| Species | Human | ||||||
| Protein Construction | 
                                                                                                                                                                                
  | 
                                                ||||||
| Purity | > 95% as determined by BisTris PAGE | ||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 258 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. | 
                                                    Immobilized HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer, His & Avi, Human, His Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-B2M Antibody, mFc Tag with the EC50 of 9.8 ng/ml determined by ELISA. »
                                                    The purity of HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer, His & Avi, Human is greater than 95% as determined by SEC-HPLC. »
                                                    HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer, His & Avi, Human on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%. »
                                                    Human NKG2C&CD94, His Tag immobilized on CM5 Chip can bind HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer, His & Avi, Human, His Tag with an affinity constant of 1.65 μM as determined in SPR assay (Biacore T200). »
                                                    Human NKG2A&CD94, mFc Tag captured on CM5 Chip via anti-mouse antibody can bind HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer, His & Avi, Human, His Tag with an affinity constant of 17.61 nM as determined in SPR assay (Biacore T200). »
| Target Background | HLA-E is a nonclassical member of the major histocompatibility complex class I gene locus. HLA-E protein shares a high level of homology with MHC Ia classical proteins: it has similar tertiary structure, associates with β2-microglobulin, and is able to present peptides to cytotoxic lymphocytes. The main function of HLA-E under normal conditions is to present peptides derived from the leader sequences of classical HLA class I proteins, thus serving for monitoring of expression of these molecules performed by cytotoxic lymphocytes. | 
| Synonyms | HLAE; sHLA-E; HLAE; MHC class I antigen E; MHC HLA-E alpha-1; MHC HLA-E alpha-2.1; MHC; QA1 | 
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.